Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Molecular Biology Test Detects Human Papillomavirus

By Biotechdaily staff writers
Posted on 30 Apr 2007
A molecular diagnostic test enables the detection of human papillomavirus (HPV) in cervical cancer surveillance.

Cervical cancer is caused in 99.7% of cases by persistent infection with HPV. More...
Most HPV infections are transient and do not induce cervical cancer. However, a small but significant number of HPV infections progress to cervical cancer. It is the expression of viral oncoproteins E6 and E7, which initiate the cervical cancer process, that makes them early cancer markers. It has also been demonstrated that genotypes 16 and 18 cause approximately 70% of cervical cancers worldwide.

Most cervical cancer surveillance methods currently in use detect viral DNA. Such testing, however, does not make it possible to most effectively assess the virus' oncogenicity. Developed by bioMérieux (Marcy l'Etoile, France), NucliSens EasyQ HPV is based on a new concept that benefits from all the latest discoveries in the field, directly determining the expression of oncogenic risk factors by detecting the mRNA of the E6 and E7 proteins.

NucliSENS HPV EasyQ is the first real-time amplification/detection test with this degree of automation to be CE-marked. It is currently available in France, the Netherlands, Belgium, Switzerland, Spain, and Austria and will be progressively marketed in other countries according to local regulations.

The test enhances the quality of women's lives by reducing the need for invasive examinations and treatments. "This new molecular diagnostic test reinforces bioMérieux's offer in the field of oncology. The test contributes to the fight against cancer and complements current methods for the detection and monitoring of cervical cancer. This new product strongly reinforces the value of our molecular biology platform, NucliSENS EasyQ, for our customers and future prospects,” said Stéphane Bancel, CEO of bioMérieux.

bioMérieux provides diagnostic solutions (reagents, instruments, software) that determine the source of disease and contamination to improve patient health and ensure consumer safety. The products are used for diagnosing infectious diseases and providing high medical value results for cardiovascular emergencies and cancer screening and monitoring.


Related Links:
bioMérieux

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: The GenoPredict assay from Predicta Biosciences is available to Tempus Life Sciences partners to support exploratory research and clinical development programs (photo courtesy of Shutterstock)

Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.